Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Editas Medicine (EDIT) has disclosed Long-Term Investments for 5 consecutive years, with $39.2 million as the latest value for Q2 2024.

  • On a quarterly basis, Long-Term Investments fell 18.44% to $39.2 million in Q2 2024 year-over-year; TTM through Jun 2024 was $39.2 million, a 18.44% decrease, with the full-year FY2023 number at $104.0 million, up 11.74% from a year prior.
  • Long-Term Investments was $39.2 million for Q2 2024 at Editas Medicine, down from $80.6 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $120.1 million in Q4 2021 to a low of $39.2 million in Q2 2024.
  • A 5-year average of $82.3 million and a median of $85.4 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 115.71% in 2021, then plummeted 40.68% in 2022.
  • Editas Medicine's Long-Term Investments stood at $109.7 million in 2020, then increased by 9.49% to $120.1 million in 2021, then decreased by 22.47% to $93.1 million in 2022, then grew by 11.74% to $104.0 million in 2023, then crashed by 62.32% to $39.2 million in 2024.
  • Per Business Quant, the three most recent readings for EDIT's Long-Term Investments are $39.2 million (Q2 2024), $80.6 million (Q1 2024), and $104.0 million (Q4 2023).